Latest news and press releases about Baxter International Inc. (BAX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution.
Price
| Price | $24.22 |
| Market Cap | $12.5B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | 26.21 |
| Dividend Yield | 0.17% |
Profitability
| Return on Equity | -16.60% |
| Return on Invested Capital | -1.61% |
| Return on Assets | -5.37% |
| Gross Margin | 30.08% |
| Operating Margin | -2.39% |
| Net Margin | -9.27% |
Related companies: ATR · AVTR · BIO · DVA · HIMS · MDGL
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BAX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks